Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

'Private Tyranny' Is Less Private Than You Think

Sohrab Ahmari inadvertently gives even more reasons to reduce the power of the state.

Reason

Newly released FBI tapes show suspect suggesting how Tylenol murders were carried out

In the 2008 footage James Lewis is seen going into detail about how the Tylenol killer would have carried out the poisonings

The Independent UK

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

S&P 500: Entertainment Giants, AI Play Lead Monday's 5 Best; Medtech Firms Sicken

Paramount and Disney, along with AI play Adobe, led the S&P 500. Dexcom and several medical products firms struggled.

Investors Business Daily

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

Fortune

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review

The Dow Jones lead the market rally, while Tesla, Netflix and Taiwan Semiconductor hit growth stocks Thursday.

Investors Business Daily

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

The Hindu

Nine 'Safer Than AT&T' Stocks Pay The Plumpest, Lead-Free Dividends

AT&T's plump dividend used to be like money in the bank. But now investors seeking income and safety might look elsewhere.

Investors Business Daily

Cheaper TB drugs for millions after global deal on patent rights agreed

Johnson & Johnson allows generic bedaquiline in 44 countries – but concerns remain about ‘stopgap’ solution

The Guardian - UK

Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign

Disease kills millions each year even though it’s curable

The Independent UK

Is Tylenol linked to autism and ADHD?

The debate over how to interpret acetaminophen science has profound implications for individuals and the public

Salon

Seven murders by cyanide-laced Tylenol will never be solved. But the prime suspect’s death brings justice

After a joint FBI task force was unable to pin the 1982 Tylenol murders on prime suspect James Lewis, special agent Roy Lane was coaxed out of retirement to carry out a daring undercover mission. He tells Bevan Hurley Lewis’ death this week ‘puts the pursuit of justice to an…

The Independent UK

James Lewis, prime suspect in Tylenol tampering cases, dead at 76

James Lewis was found unresponsive at his residence in Cambridge, Mass. His death was determined to be not suspicious, police said.

Chicago Sun-Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Seven Of The Top 10 Most-Valuable Stocks Are Still Cheap, Analysts Say

Think you missed your chance to profit on the S&P 500's most valuable stocks? Good news: analysts say there's still upside for most of them.

Fortune

Fortune 500 companies and CEOs react to end of affirmative action

Fortune 500 companies, including Salesforce and Microsoft, reacted to the Supreme Court's decision to reject affirmative action at U.S. colleges and universities.

The Guardian - UK

‘People are like, Wow!’: the man trying to make condoms sexy

The long read: It has been said that condoms share marketing characteristics with napalm and funerals. But it is Ben Wilson’s mission to make us believe they are key to human happiness

Barchart

Chart of the Day: Is Johnson & Johnson Poised for a Breakout?

The Chart of the Day belongs to the healthcare company Johnson & Johnson (JNJ) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the...

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Opioid settlement payouts made public

Opioid settlement funds have been doled out. In some cases, it's not clear how they're being spent

WEKU

Opioid settlement payouts are now public — and we know how much local governments got

KFF Health News obtained documents showing the exact dollar amounts — down to the cent — that local governments have been paid in 2022 and 2023 in lawsuit settlements from the opioid crisis.

Fortune

Future Fortune 500 CEOs: 11 up-and-comers that leadership experts see as generational standout bosses

Fortune has identified 11 CEO stars in the making—many of them already in the C-suite, and all potential large-company CEOs.

Newcastle Herald

Ex-chief judge seeks best deal for pelvic mesh victims

"It was impossible not to be affected by the poignant stories told."

StockNews.com

Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell?

Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.

Investors Business Daily

Short Sellers Won't Bet Against Eight Rock-Solid Buffett-Like Stocks

Short sellers aren't afraid of many stocks in the S&P 500. But one stock they won't touch is Warren Buffett's Berkshire Hathaway.

Investors Business Daily

Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm

Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.